TNF Pharmaceuticals, Inc.

TNF Pharmaceuticals, Inc., formerly known as MyMD Pharmaceuticals, Inc., is a clinical stage pharmaceutical company dedicated to extending healthy lifespan. The company is listed on Nasdaq under the ticker symbol TNFA and has been operating since 2014. TNF Pharmaceuticals is focused on developing two innovative therapeutic platforms that target the root causes of diseases instead of just addressing the symptoms. One of their platforms, MYMD-1®, is centered around a clinical stage small molecule that regulates the immune system to control TNF-α and other pro-inflammatory cell signaling cytokines, which drive chronic inflammation. This platform is aimed at treating diseases and disorders characterized by acute or chronic inflammation. The company's second platform, Supera-CBD, focuses on the development of novel synthetic derivatives of cannabidiol (CBD) to address chronic pain, addiction, and epilepsy. This platform aims to tap into the rapidly growing CBD market, which includes both FDA-approved drugs and unregulated CBD products. TNF Pharmaceuticals is headquartered in the United States. As of now, details about the last investment and the involved investors are not available. Overall, TNF Pharmaceuticals is leveraging its clinical stage and commitment to addressing the root causes of diseases to make an impact in the pharmaceutical industry.